Skip to main content
Triangle logo TriangleGet started

Docetaxel (NCT06223568)

Phase II Trial of Neoadjuvant Chemotherapy (NAC) Alone or in Combination With Immunotherapy Vaccine PRGN-2009 in Subjects With Newly Diagnosed HPV-Associated Oropharyngeal (Head and Neck) Cancer: a one-minute explainerNCT062235681 min

Docetaxel trial for Squamous Cell Carcinoma of the Head and Neck (NCT06223568). This is a short film with English narration. The transcript is on this page, and the written brief is separate.

What the film says

Read the transcript

This trial is for people aged 18–120 with newly diagnosed, resectable stage I or II HPV-positive oropharyngeal cancer. Smoking-history limits apply, with required surgery and research tissue.

The idea: add PRGN-2009, a vaccine designed to increase HPV-specific T-cell responses, to chemotherapy before surgery. Random assignment gives docetaxel and cisplatin every three weeks for three cycles, with or without four vaccine injections. Surgery follows; pathology determines whether radiation is needed. Researchers assess surgical tumor response.

This phase 2 study plans 70 patients. Clint Allen leads at NIH in Bethesda, the sole recruiting US site.

Public record; not medical advice.

Read the full brief →

Already in a trial?

It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.

Organize my trial

7-day free trial, then $9 a month. Cancel anytime.